1. Design, synthesis, characterization, and in vitro evaluation of a new cross-linked hyaluronic acid for pharmaceutical and cosmetic applications
- Author
-
Larissa Gomes dos Reis, Daniela Traini, Elisa Durini, Alessandra Semenzato, Anna Baldisserotto, Giovanni Tafuro, Dina M. Silva, Silvia Vertuani, Stefano Manfredini, Massimo Terno, Sabrina Sciabica, and Luisa Canilli
- Subjects
Biocompatibility ,Hyaluronic acid ,Pharmaceutical Science ,Article ,NO ,chemistry.chemical_compound ,Pharmacy and materia medica ,Hyaluronidase ,medicine ,LS7_3 ,Cytotoxicity ,Cross-linking ,chemistry.chemical_classification ,LS7_8 ,Chemical modification ,Biomaterial ,In vitro ,Amino acid ,hyaluronic acid ,cross-linking ,biocompatibility ,RS1-441 ,chemistry ,Biochemistry ,medicine.drug - Abstract
Hyaluronic acid (HA), an excellent biomaterial with unique bio properties, is currently one of the most interesting polymers for many biomedical and cosmetic applications. However, several of its potential benefits are limited as it is rapidly degraded by hyaluronidase enzymes. To improve the half-life and consequently increase performance, native HA has been modified through cross-linking reactions with a natural and biocompatible amino acid, Ornithine, to overcome the potential toxicity commonly associated with traditional linkers. 2-chloro-dimethoxy-1,3,5-triazine/4-methylmorpholine (CDMT/NMM) was used as an activating agent. The new product (HA–Orn) was extensively characterized to confirm the chemical modification, and rheological analysis showed a gel-like profile. In vitro degradation experiments showed an improved resistance profile against enzymatic digestions. Furthermore, in vitro cytotoxicity studies were performed on lung cell lines (Calu-3 and H441), which showed no cytotoxicity.
- Published
- 2021